WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
EMMA COWING: Humza Yousaf's obsession with gender politics showed an absolute contempt for women
Xi calls for solid efforts to further energize China's central region
Iranian FM opens new consulate in Damascus following Israeli strike
Olivier Awards 2024: Beaming Sarah Snook reunites with Succession co
FCC fines wireless carriers for sharing user locations without consent
Drake pushes back after Rick Ross accused him of getting a nose job in Champagne Moments lyrics
Hayao Miyazaki's animated fantasy stays atop Chinese box office
China pledges constructive role in resolving Myanmar's Rakhine State crisis
2 men are charged with cutting down famous 150
Andrew Scott speaks out on his 'wonderful' friendship with All Of Us Strangers co